Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119428 · ClinicalTrials.gov registry record · Phase 1
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by OncoMed Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03119428 is a Phase 1 study that was terminated before completion, run by OncoMed Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT03119428, a Phase 1 study, was terminated before completion, sponsored by OncoMed Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of OMP-31M32 as a single agent or in combination with nivolumab. OMP-313M32 is an experimental anti-TIGIT antibody that was developed to block TIGIT from binding PVR allowing the body's T-cells to destroy cancer cells.
Interventions
- DRUG Nivolumab
- DRUG OMP-313M32
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-05-02 |
| Est. Completion | 2019-05-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03119428
The ClinicalTrials.gov registry entry for NCT03119428 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OncoMed Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03119428 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03119428 about?
NCT03119428 is a clinical study titled "A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors". The purpose of this study is to evaluate the safety and tolerability of OMP-31M32 as a single agent or in combination with nivolumab. OMP-313M32 is an experimental anti-TIGIT antibody that was developed to block TIGIT from binding PVR allowing the body's T-cells to destroy cancer cells.
What is the current status of trial NCT03119428?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-05-02. Estimated completion is 2019-05-15.
What interventions are being tested in trial NCT03119428?
The interventions under investigation include: Nivolumab (DRUG), OMP-313M32 (DRUG).
Who is sponsoring clinical trial NCT03119428?
This trial is sponsored by OncoMed Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.